Bordetella pertussis chromogenic culture medium and its application
The use of chromogenic culture medium has solved the problems of long culture cycle and difficult identification of Bordetella pertussis, and has enabled rapid and highly specific isolation and identification, which is suitable for the isolation and identification of Bordetella pertussis.
Patent Information
- Application Number
- CN202310433171.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-21
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-04-21
AI Technical Summary
Existing technologies for the culture and identification of Bordetella pertussis suffer from problems such as long culture cycles, susceptibility to contamination by other bacteria, and inaccurate results. In particular, culture methods, immunological detection, and PCR detection are time-consuming, have high false positive rates, and cannot distinguish live bacteria.
A chromogenic culture medium containing specific nutrients and antibacterial agents is provided, which can determine the results by colony color changes within 72 hours. It has high specificity and is suitable for isolating and identifying Bordetella pertussis.
Chromogenic culture media can rapidly and specifically isolate and identify Bordetella pertussis, shortening the culture time, reducing interference from other bacteria, and improving the accuracy and efficiency of detection.
Smart Images

Figure BDA0004191030190000071 
Figure BDA0004191030190000081 
Figure BDA0004191030190000091
Abstract
Description
Technical Field
[0001] This invention relates to the field of biotechnology, and in particular to a chromogenic culture medium for Bordetella pertussis and its application. Background Technology
[0002] Pertussis, or whooping cough, is an acute respiratory infectious disease caused by Bordetella pertussis. It is named "whooping cough" because its course can last for several months. Patients may experience paroxysmal spasmodic coughing accompanied by a deep, whooping inspiratory sound; severe cases can lead to death. It typically affects children under 5 years old, with infants being more prone to developing severe illness and having a mortality rate as high as 10%. In the early 20th century, with the development and widespread use of vaccines, the incidence of pertussis decreased by more than 90% in European and American countries implementing expanded immunization programs, and the mortality rate also dropped significantly, effectively controlling the disease. However, since the 1990s, many European and American countries have experienced pertussis outbreaks. Despite high vaccine coverage, the incidence rate in infants and young children has increased, and cases have also appeared in adolescents and adults. European and American countries refer to this change in the pertussis epidemic trend as a "whooping resurgence." In recent years, the incidence of pertussis in my country has also shown an upward trend. In 2017, 10,390 cases of pertussis were reported in China, and the number of reported cases has increased for three consecutive years from 2017 to 2019. Of particular concern is the increasing number of pertussis cases among vaccinated adolescents and adults. Misdiagnosis is common in adolescents and adults due to atypical clinical symptoms, and these cases are often significant sources of pertussis infection in infants and young children. Therefore, the culture and identification of Bordetella pertussis is of great clinical importance. Existing detection methods include bacterial culture, immunological detection, and molecular biology methods.
[0003] 1. Bacterial culture method
[0004] Pathogen culture and detection is the "gold standard" for diagnosing Bordetella pertussis infection. Bordetella pertussis has high nutritional requirements and is sensitive to metabolic products such as fatty acids, heavy metal ions, and peroxides produced during its growth, which affect its growth. It requires culture media containing carbon, blood, and starch, such as Bogin's medium and activated charcoal medium for pertussis. Identification of the cultured bacteria is also challenging; conventional bacterial identification instruments cannot provide accurate results. In China, serum agglutination reaction is the primary method of identification, although mass spectrometry can also be used. Currently, for the culture method to detect Bordetella pertussis, samples are first inoculated onto a pertussis-selective medium and incubated at 37°C. The culture dishes are then examined daily starting after 3 days until day 14. If grayish-white, round, translucent suspected colonies are observed, Gram staining, catalase testing, and Bordetella pertussis serum slide agglutination test are performed. Microscopic examination reveals short, Gram-negative bacilli with positive catalase, and colonies confirmed positive by pertussis serum agglutination test are identified as Bordetella pertussis. Alternatively, mass spectrometry can be used to identify Bordetella pertussis. Bordetella pertussis grows slowly and takes a long time to culture, requiring 2 to 3 weeks. Due to the long time required, it is easy for contamination by other bacteria, especially fungi, to occur during the culture process.
[0005] 2. Immunological detection methods
[0006] 2.1 Direct Fluorescent Antibody Assay (DFA)
[0007] DFA is simple to perform and inexpensive, but its specificity varies greatly, its sensitivity is not high, the interpretation of results is subjective, the fluorescence is easily quenched, and there is also cross-reactivity with other pathogens in the nasopharynx. Therefore, in clinical applications, it is necessary to combine the symptoms of suspected patients with other relevant test results to make a diagnosis. It is no longer recommended for the diagnosis of pertussis.
[0008] 2.2 Serological testing
[0009] Following infection with Bordetella pertussis or after immunization, the body produces different antibodies against the pertussis antigen, which can be detected serologically. Pertussis toxin (PTx) is a unique antigen of Bordetella pertussis and is easily standardized and detected. The optimal time for serological testing is 2–8 weeks after the onset of cough, when antibody titers are at their highest, making it more useful for diagnosing the later stages of the disease. Caution should be exercised when performing serological diagnosis on suspected patients who have recently been vaccinated against pertussis; a diagnosis should be made by comparing clinical symptoms, acute-phase serum, and convalescent-phase serum. Furthermore, serological testing is not applicable to the diagnosis of pertussis in infants. International studies have shown that in infants, 82.2% were diagnosed with pertussis by culture or PCR, while only 39.6% were positive by PTx serological testing.
[0010] Serological testing has always been an important tool in epidemiological investigations. However, serological testing is often more useful for the clinical diagnosis of pertussis in its later stages.
[0011] 3. Molecular biological detection methods
[0012] With the development of molecular biotechnology, PCR technology has been increasingly applied to the detection of pertussis infection. It boasts high sensitivity, good specificity, a high positive detection rate, and short processing time, making it a rapid, accurate, and highly sensitive detection method. The positive rate of PCR for detecting Bordetella pertussis is higher than that of bacterial culture. However, this method also has certain limitations, such as low bacterial content on the swab sample and failure to extract bacterial target genes. Different manufacturers' detection reagents target specific sequences that vary considerably. Currently, the main target gene sequences include the insertion sequences IS481, IS1001, IS1002, the upstream promoter region of the pertussis toxin gene, pertussis adhesin, and outer membrane porin, etc., and the detection specificity of different target sequences of pertussis toxin varies. PCR technology also needs to be aware of the false positive problem, as the target sequences are not unique to Bordetella pertussis; other bacteria in the Bordetella genus also have the same sequences. In recent years, the main PCR techniques used for pertussis diagnosis include multiplex PCR, nested primers PCR, and real-time PCR.
[0013] Culture-based detection of Bordetella pertussis has a low positive detection rate, is complex, and has a long culture period (2-3 weeks) requiring results. In some cases, patients have already recovered before the culture results are available, hindering timely clinical diagnosis and treatment of pertussis. Furthermore, the extended time required increases the risk of contamination by other microorganisms, especially fungi, during the culture process. Clinical samples often contain numerous contaminants that can mask pertussis growth. Selecting suspicious colonies (white, round, translucent suspected colonies) requires significant experience from the laboratory personnel and is prone to missed detection. Serum agglutination tests or mass spectrometry are necessary after culture to identify Bordetella pertussis.
[0014] Direct fluorescent antibody assay (DFA) has high specificity and low sensitivity, the results are subjective, the fluorescence is easily quenched, and there is also cross-reactivity with other pathogens in the nasopharynx. It is no longer recommended for the diagnosis of pertussis.
[0015] While serological testing methods offer high sensitivity and specificity, and are simple and rapid, they are not sensitive for patients in the acute phase and cannot accurately diagnose patients who have recently been vaccinated against pertussis. Human pertussis IgG (PT-IgG) is the most sensitive diagnostic agent for pertussis, but testing requires collecting duplicate serum samples to detect PT-IgG. If the antibody level in the second serum sample is 3-4 times higher than in the first, the accuracy of the diagnosis of pertussis increases significantly. However, collecting duplicate serum samples is difficult in practice; therefore, most countries currently use different serum PT-IgG thresholds for single-sera testing.
[0016] The accuracy of PCR methods is related to the specific detection sequences targeted by the test reagents produced by different manufacturers. Different manufacturers choose significantly different specific detection sequences, and different target sequences have varying detection specificities. Furthermore, some target sequences are not specific to Bordetella pertussis; other bacteria in the Bordetella genus also have the same sequences, thus affecting the product's specificity. PCR detection cannot obtain cultured colonies for subsequent confirmatory verification, therefore false positives cannot be ruled out.
[0017] Besides the culture method, antibody detection, serological detection, PCR detection, etc., cannot distinguish whether Bordetella pertussis is alive, and cannot obtain a culture, so subsequent verification tests and drug sensitivity tests cannot be performed. Summary of the Invention
[0018] In view of this, the present invention provides a chromogenic culture medium for Bordetella pertussis and its application. The present invention provides a chromogenic culture medium for simultaneously culturing and identifying Bordetella pertussis in samples. It is easy to prepare, shortens the process, has a short culture cycle, and allows for result determination based on color changes after 72 hours of culture. It exhibits high specificity and selectivity. The present invention is also applicable to the culture and identification of isolated strains.
[0019] To achieve the above-mentioned objectives, the present invention provides the following technical solution:
[0020] The present invention provides a culture medium comprising tryptone, gelatin peptone, acid-hydrolyzed casein, beef meal, sodium glycerophosphate, mannitol, MOPS, calcium chloride, sodium L-glutamate, dipotassium hydrogen phosphate, sodium pyruvate, copper salt, phosphatase substrate, soybean lecithin, antibacterial agent, L-cysteine hydrochloride, NAD, and agar powder.
[0021] In some specific embodiments of the present invention, the culture medium further includes water.
[0022] In some specific embodiments of the present invention, the copper salt includes copper sulfate and / or copper chloride.
[0023] In some specific embodiments of the present invention, the copper salt includes CuSO4·5H2O, copper chloride, copper phosphate, or other salts of copper ions.
[0024] In some specific embodiments of the present invention, the phosphatase substrate includes:
[0025] (I) 5-bromo-6-chloro-3-indole-phosphate, 5-bromo-4-chloro-3-indole-phosphate and / or 6-chloro-3-indole-phosphate; and / or
[0026] (II) and (I) corresponding salts;
[0027] The corresponding salts of (I) include 5-bromo-6-chloro-3-indole-phosphate p-tolueneammonium salt and / or 5-bromo-4-chloro-3-indole-phosphate sodium salt.
[0028] In some specific embodiments of the present invention, the antibacterial agent includes cephalexin, vancomycin, nystatin, amphotericin B, and / or caspofungin.
[0029] In some specific embodiments of the present invention, the culture medium further includes glycosidase-based chromogenic substrates;
[0030] The glycosidase-based chromogenic substrates include β-glucosidase substrates and / or β-galactosidase substrates.
[0031] In some specific embodiments of the present invention, the culture medium comprises 2-10 g / L tryptone, 2-10 g / L gelatin peptone, 2-10 g / L acid-hydrolyzed casein, 1-7 g / L beef meal, 0.1-2 g / L sodium glycerophosphate, 0.5-3 g / L mannitol, and MOPS. 0.5–3 g / L, calcium chloride 0.1–2 g / L, L-glutamate sodium 2–10 g / L, dipotassium hydrogen phosphate 0.5–3 g / L, sodium pyruvate 1–5 g / L, copper sulfate 0.02–0.1 g / L, phosphatase substrate 0.1–0.5 g / L, soybean lecithin 1–5 g / L, cephalexin 0.004–0.04 g / L, vancomycin 0.05–0.5 g / L, nystatin 0.01–0.1 g / L, amphotericin B 0.01–0.1 g / L, L-cysteine hydrochloride 0.5–2 g / L, NAD 0.5–2 g / L, and agar powder 7–15 g / L.
[0032] In some specific embodiments of the present invention, the culture medium exists in the form of culture medium plates or culture medium dry powder.
[0033] The present invention also provides the use of the culture medium in the preparation of any of the following:
[0034] (I) Products that isolate Bordetella pertussis; and / or
[0035] (II) Products containing Baumannii pertussis; and / or
[0036] (III) Products identified as Bordetella pertussis; and / or
[0037] (IV) Pertussis detection products.
[0038] The present invention also provides a product comprising the culture medium.
[0039] This invention includes, but is not limited to, achieving the following beneficial effects:
[0040] This invention provides a chromogenic culture medium for the simultaneous isolation, culture, and identification of Bordetella pertussis in samples. This medium not only achieves specific chromogenic development of Bordetella pertussis but also shortens the culture time, simplifies the operation, shortens the process, saves time, and yields Bordetella pertussis cultures. This invention is also applicable to the culture and identification of isolated strains. Attached Figure Description
[0041] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the description of the embodiments or the prior art will be briefly introduced below.
[0042] Figure 1 This shows the results of the 100-day cough colorimetric experiment;
[0043] Figure 2 This shows the results of the colorimetric assay for 200-day cough.
[0044] Figure 3 The results of the colorimetric assay for 300-day cough are shown.
[0045] Figure 4 This shows the results of the colorimetric assay for 400-day cough.
[0046] Figure 5 The results of the colorimetric assay for 500-day cough are shown.
[0047] Figure 6 The results of the colorimetric assay for 600-day cough are shown.
[0048] Figure 7 The results of the 700-day cough colorimetric experiment are shown.
[0049] Figure 8 The results of the color development of mixed bacteria in Experiment 1 are shown.
[0050] Figure 9 The results of color development of the two mixed bacteria are shown in Experiment 2;
[0051] Figure 10 The results of color development of three contaminating bacteria are shown in the experiment;
[0052] Figure 11 The results of color development of four types of bacteria are shown in the experiment.
[0053] Figure 12 The results of color development of five types of bacteria in the experiment are shown.
[0054] Figure 13 The results of colorimetric analysis of six different bacteria are shown in the experiment.
[0055] Figure 14 The results of color development of seven different bacteria in the experiment are shown.
[0056] Figure 15 Clinical sample 1 shows the results of this invention;
[0057] Figure 16 The results of existing methods are shown for clinical sample 1;
[0058] Figure 17 Clinical sample 2 shows the results of this invention;
[0059] Figure 18 The results of existing methods are shown for clinical sample 2;
[0060] Figure 19 Clinical sample 3 shows the results of this invention;
[0061] Figure 20 The results of existing methods are shown for clinical sample 3. Detailed Implementation
[0062] This invention discloses a chromogenic culture medium for Bordetella pertussis and its applications. Those skilled in the art can refer to the content of this document and appropriately modify the process parameters to achieve the desired results. It is particularly important to note that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in this invention. The methods and applications of this invention have been described through preferred embodiments. Those skilled in the art can clearly modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit, and scope of this invention to realize and apply the technology of this invention.
[0063] The Bordetella pertussis chromogenic culture medium of the present invention contains nutrients supporting the growth of Bordetella pertussis, an antibacterial agent inhibiting interference from other bacteria, and a chromogenic agent that specifically develops the color of Bordetella pertussis. It can be used not only for the culture and identification of obtained isolates, but also for the direct culture and identification of Bordetella pertussis using samples.
[0064] The bacteria mentioned include various types, such as Klebsiella pneumoniae, Escherichia coli, and Enterobacter cloacae, among others. The attached image shows one example. Gram-positive bacteria such as Enterococcus and Staphylococcus, as well as Candida, can be inhibited. Some bacteria that are also Gram-negative, like those causing pertussis (whooping cough), such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae, cannot be inhibited by drugs. This invention enables different color development of these bacteria compared to pertussis.
[0065] The culture medium can be a pre-made culture medium plate or a dry culture medium powder. When using it, water is added, it is heated, and then it is prepared into a culture medium plate.
[0066] The culture medium components include: tryptone 2–10 g / L, gelatin peptone 2–10 g / L, acid-hydrolyzed casein 2–10 g / L, beef meal 1–7 g / L, sodium glycerophosphate 0.1–2 g / L, mannitol 0.5–3 g / L, and MOPS. 0.5–3 g / L, calcium chloride 0.1–2 g / L, L-glutamate sodium 2–10 g / L, dipotassium hydrogen phosphate 0.5–3 g / L, sodium pyruvate 1–5 g / L, copper sulfate 0.02–0.1 g / L, phosphatase substrate 0.1–0.5 g / L, soybean lecithin 1–5 g / L, cephalexin 0.004–0.04 g / L, vancomycin 0.05–0.5 g / L, nystatin 0.01–0.1 g / L, amphotericin B 0.01–0.1 g / L, L-cysteine hydrochloride 0.5–2 g / L, NAD 0.5–2 g / L, agar powder 7–15 g / L;
[0067] The key components are: soybean lecithin 1-5 g / L, copper sulfate 0.02-0.1 g / L, and phosphatase substrate 0.05-0.5 g / L;
[0068] The phosphatase substrate may be, but is not limited to, 5-bromo-6-chloro-3-indole-phosphate, 5-bromo-4-chloro-3-indole-phosphate, 6-chloro-3-indole-phosphate, and their corresponding salts, such as p-tolueneammonium salt of 5-bromo-6-chloro-3-indole-phosphate, sodium salt of 5-bromo-4-chloro-3-indole-phosphate, etc.
[0069] CuSO4·5H2O can also be a salt of other copper ions, such as copper chloride;
[0070] This chromogenic medium can shorten the culture time for pertussis, allowing results to be determined after 72 hours of culture.
[0071] The chromogenic medium is used to determine the culture results based on the color of the colonies after culture. Bordetella pertussis colonies are light brown to dark brown, while other bacteria do not grow or do not show light brown to dark brown colonies.
[0072] To further improve specificity, other glycoside chromogenic substrates, such as β-glucosidase substrates and β-galactosidase substrates, can be added to this culture medium.
[0073] Existing methods suffer from two main drawbacks: firstly, isolating and culturing Bordetella pertussis is difficult, with long culture cycles and sensitivity affected by numerous factors; secondly, it cannot be used to identify pertussis through culture. This invention provides a chromogenic culture medium for simultaneously culturing and identifying Bordetella pertussis in samples, based on traditional methods. This medium is easy to prepare, shortens the process, has a short culture cycle (resulting in results after 72 hours based on color changes), and exhibits high specificity and selectivity. This invention is also applicable to the culture and identification of isolated strains.
[0074] The Bordetella pertussis used in this invention is the ATCC standard strain, strain number ATCC9797, purchase batch number: 70022065, purchased from Beijing Zhongyuan.
[0075] Unless otherwise specified, the raw materials and reagents used in the Bordetella pertussis chromogenic culture medium provided by this invention and its application can all be purchased from the market.
[0076] The present invention will be further illustrated below with reference to the embodiments:
[0077] Example 1: Preparation and color development of culture medium
[0078] Experimental data: The experimental scheme and colorimetric results are shown in Table 1. Figures 1-14 As shown:
[0079] Table 1. Preparation and color development of culture media
[0080]
[0081]
[0082]
[0083] Example 2: Detection of clinical samples using culture medium
[0084] The donors of the clinical samples were patients with cough symptoms. The clinical samples were simultaneously tested using the culture medium of this invention and existing detection methods. The culture medium of this invention was prepared according to Example 1 and made into agar plates, with swabs streaked into sputum samples; existing detection methods use blood agar plates, with swabs streaked into sputum samples. The results are shown in Table 2. Figures 15-20 As shown:
[0085] Table 2. Detection of clinical samples using culture medium
[0086]
[0087] Results analysis: The culture medium of the present invention can be used for the detection of Bordetella pertussis, achieving colony-specific color development and effectively inhibiting the growth of other bacteria. Existing methods cannot distinguish between pertussis and other microorganisms in clinical samples. The present invention realizes the isolation, culture and identification of pertussis.
[0088] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A culture medium, characterized in that, Including tryptone 2-10 g / L, gelatin peptone 2-10 g / L, acid-hydrolyzed casein 2-10 g / L, beef meal 1-7 g / L, sodium glycerophosphate 0.1-2 g / L, mannitol 0.5-3 g / L, MOPS 0.5~3g / L, calcium chloride 0.1~2g / L, L-glutamate sodium 2~10g / L, dipotassium hydrogen phosphate 0.5~3g / L, sodium pyruvate 1~5g / L, copper sulfate 0.02~0.1g / L, phosphatase substrate 0.1~0.5g / L, soybean lecithin 1~5g / L, cephalexin 0.004~0.04g / L, vancomycin 0.05~0.5g / L, nystatin 0.01~0.1g / L, amphotericin B 0.01~0.1g / L, L-cysteine hydrochloride 0.5~2g / L, NAD 0.5~2g / L, and agar powder 7~15g / L; The phosphatase substrates include p-tolueneammonium 5-bromo-6-chloro-3-indole-phosphate and sodium 5-bromo-4-chloro-3-indole-phosphate; The culture medium also includes glycosidase-based chromogenic substrates; the glycosidase-based chromogenic substrates include β-glucosidase substrates and / or β-galactosidase substrates.
2. The culture medium as described in claim 1, characterized in that, It also includes water.
3. The culture medium as described in claim 1, characterized in that, The culture medium exists in the form of culture medium plates or culture medium dry powder.
4. The use of the culture medium according to any one of claims 1 to 3 in the preparation of any of the following; (I) Products that isolate Bordetella pertussis; and / or (II) Products containing Bordetella pertussis; and / or (III) Products identified as having Bordetella pertussis; and / or (IV) Pertussis detection products.
Citation Information
Patent Citations
Bordetella vaccines
CA2013571A1
Staphylococcus aureus specific chromogenic medium
CN103642894A
